Clinical

Dataset Information

0

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors


ABSTRACT: This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.

DISEASE(S): Adenocarcinoma,Kras G12r,Kras G12s,Nras G12v,Kras G12v,Colorectal Cancer,Nras G12s,Nras G12r,Pancreatic Ductal Adenocarcinoma,Kras G12a,Kras G12c,Kras G13d,Kras G12d,Colon Cancer,Nras G12c,Colorectal Neoplasms,Nras G12d

PROVIDER: 8247 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2374931 | ecrin-mdr-crc
2009-09-12 | GSE18023 | GEO
2020-01-08 | E-MTAB-8057 | biostudies-arrayexpress
2017-06-17 | GSE98630 | GEO
2023-02-20 | PXD036811 | Pride
2010-05-05 | E-GEOD-18023 | biostudies-arrayexpress
2011-04-01 | GSE23442 | GEO
2004-07-27 | GSE1594 | GEO
2023-04-17 | GSE224249 | GEO
2011-12-02 | E-GEOD-34070 | biostudies-arrayexpress